Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹8,267 Cr
Revenue (TTM)
₹4,726 Cr
Net Profit (TTM)
₹511 Cr
ROE
17.5 %
ROCE
16.6 %
P/E Ratio
16.2
P/B Ratio
2.8
Industry P/E
28.7
EV/EBITDA
9.3
Div. Yield
0.4 %
Debt to Equity
0.7
Book Value
₹321.6
EPS
₹59.7
Face value
10
Shares outstanding
92,172,714
CFO
₹2,466.77 Cr
EBITDA
₹4,462.43 Cr
Net Profit
₹408.87 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| -0.3 | 2.3 | 1.0 | 41.7 | 53.7 | 5.4 | 0.5 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| 27.8 | 0.8 | 85.6 | -21.7 | -49.3 | 142.9 | -22.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Strides Pharma
|
897.6 | 8,267.0 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.2 | 2.8 |
| 2,943.9 | 36,792.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.3 | 8.0 | |
| 8,370.5 | 21,081.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 104.9 | 25.4 | |
| 1,621.8 | 12,361.0 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.1 | 3.7 | |
| 1,286.2 | 18,018.2 | 3,078.2 | 469.4 | 26.4 | 14.9 | 41.7 | 5.0 | |
| 2,084.9 | 33,495.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 44.4 | 8.4 | |
| 4,724.5 | 21,608.7 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.3 | 5.4 | |
| 4,819.4 | 8,049.4 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.4 | 11.5 | |
| 3,408.1 | 7,865.0 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.1 | 10.5 | |
| 314.8 | 6,185.3 | 1,432.0 | 149.0 | 19.1 | 7.9 | 41.2 | 2.5 |
2 min read•By Jugal Harpalani
1 min read•By Research Desk
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The... company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. Read more
Incorporated
1990
Chairman
Arun Kumar
Managing Director
Badree Komandur
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Strides Pharma Science Ltd is ₹897.60 (NSE) and ₹895.75 (BSE) as of 19-Mar-2026 15:59 IST. Strides Pharma Science Ltd has given a return of 53.71% in the last 3 years.
The P/E ratio of Strides Pharma Science Ltd is 16.16 times as on 19-Mar-2026, a 44 discount to its peers’ median range of 28.70 times.
The P/B ratio of Strides Pharma Science Ltd is 2.79 times as on 19-Mar-2026, a 39 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
1.72
|
2.42
|
|
2024
|
0.00
|
3.39
|
|
2023
|
0.00
|
1.18
|
|
2022
|
0.00
|
1.32
|
|
2021
|
28.21
|
2.73
|
The 52-week high and low of Strides Pharma Science Ltd are Rs 1,025.00 and Rs 513.05 as of 19-Mar-2026.
Strides Pharma Science Ltd has a market capitalisation of ₹ 8,267 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Strides Pharma Science Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-9.45
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.